Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

Bridgebio Pharma Inc.’s data from the phase II study with infigratinib in achondroplasia “swings the pendulum of debate ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has announced positive and sustained results from its Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. The trial, known ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

Layla-Grace is a happy, determined and chatty little girl who loves music and playing outside. The 18-month-old has been ...

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

Before Liz announced that her daughter would be average height, her parents Trent and Amber Johnston had their fingers not-so ...

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.